A new risk stratification model for idiopathic pulmonary fibrosis could shift treatment from passive monitoring to active, goal-oriented care.

Regulatory officials have granted Molbreevi priority review and assigned a goal date of Aug. 22, 2026. If approved, Molbreevi will be priced between $400,000 and $500,000 per year.

Insufficient evidence exists to show efficacy of novel hypersensitivity pneumonitis therapies, indicating the need for clinical protocols.

Relapse rates over 3 years did not differ with glucocorticoid withdrawal vs maintenance among patients with stable SjD-ILD.

Cough sounds carry disease-specific acoustic signatures. By analysing these signatures using an AI-based algorithm, the ...

Lindsay Curtis is a health & medical writer in South Florida. She worked as a communications professional for health nonprofits and the University of Toronto’s Faculty of Medicine and Faculty of ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

“Iron Lung,” a horror movie directed and funded by the video creator known as Markiplier, pulled in $22 million in its first weekend after fans across the country requested screenings. By Megan ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. LOS ANGELES, CALIFORNIA - DECEMBER 05: Mark "Markiplier" Fischbach attends the IRON LUNG Los ...